No abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

No abstract

No abstract

There is an increased prevalence of inflammatory bowel diseases [Crohn's disease (CD) and ulcerative colitis (UC)] in HS. The frequency of chronic inflammatory intestinal disorders (CIID) (including, but not exclusively limited to CD and UC; eg. microscopic colitis, segmental colitis), diagnosed by colonoscopy and bowel histology, however, has not been elucidated. Because of its clinical relevance, we aimed to determine the frequency of CIID in HS. For all consented patients (n¼74) first visiting our HS Clinic a detailed history was taken, including gastrointestinal (GI) symptoms, and thorough skin examination was performed. All were referred to a gastroenterologist for colonoscopy and stool calprotectin test. Laboratory analyses for C-reactive protein, blood count, serum NOD2 polimorphism, ASCA levels were also completed. We created two patient groups (HS-only and HS with CIID) and compared the clinical, and laboratory data. The frequency of CIID among HS patients was 28,4% (21/ 74). In this group we detected significantly lower BMI and more severe HS (Hurley stage III) when compared to HS without CIID. We identified significantly higher amount of positive calprotectin test rates, as well as elevated ASCA IgG levels in the group of HS with CIID compared with the HS-only group. No difference was found in smoking habits and NOD2 polymorphism. Stool calprotectin test showed high sensitivity and specificity rate diagnosing CIID in HS. Based on our data, the presence of CIID correlated with lower BMI, and more severe HS activity, even in patients with no GI symptoms. Calprotectin test is a useful tool to identify the presence of CIID in HS that makes HS probably the highest correlating skin disease to bowel inflammations. These results promote a strong working relationship between the practising gastroenterologists and dermatologists.